One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
IN THE LITERATURE
Stan Deresinski
doi : 10.1093/cid/ciad139
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages i–ii,
How Infectious Disease Experts Impacted the Coronavirus Disease 2019 Response: Lessons From the Front Lines
Amesh Adalja, Daniel P McQuillen, Diane Meyer
doi : 10.1093/cid/ciad137
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1875–1878
In this article, we summarize findings from research conducted by the Johns Hopkins Center for Health Security and the Infectious Diseases Society of America to understand infectious disease (ID) workforce contributions to the coronavirus disease 2019 (COVID-19) response and their impacts. ID experts were found to have made diverse and unique contributions that went well beyond their usual responsibilities, with many spending several hours a week on these activities without additional compensation.
CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study
Mohamed N’dongo Sangaré, Jean-Guy Baril, Alexandra de Pokomandy, Marina Klein, Réjean Thomas, Cécile Tremblay, Costa Pexos, Madeleine Durand, Seerat Chawla, Louise Laporte, Helen Trottier
doi : 10.1093/cid/ciad056
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1879–1888
The impact of different therapeutic classes of drugs in antiretroviral therapy (ART) regimens on the CD4/CD8 ratio is not well documented in people treated for HIV. The objective of this study was to analyze the long-term effect of exposure to integrase strand transfer inhibitor (INSTI) on CD4/CD8 ratio compared with nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) among ART-treated persons with HIV (PWH).
Epidemiology of Invasive Nontypeable Haemophilus influenzae Disease—United States, 2008–2019
Sara E Oliver, Amy B Rubis, Heidi M Soeters, Arthur Reingold, Meghan Barnes, Susan Petit, Monica M Farley, Lee H Harrison, Kathy Como-Sabetti, Sarah A Khanlian, Rachel Wester, Ann Thomas, William Schaffner, Henju Marjuki, Xin Wang, Susan Hariri
doi : 10.1093/cid/ciad054
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1889–1895
Nontypeable Haemophilus influenzae (NTHi) is the most common cause of invasive H. influenzae disease in the United States (US). We evaluated the epidemiology of invasive NTHi disease in the US, including among pregnant women, infants, and people with human immunodeficiency virus (PWH).
Incidence of Childbirth, Pregnancy, Spontaneous Abortion, and Induced Abortion Among Women With Human Immunodeficiency Virus in a Nationwide Matched Cohort Study
Fie W Paulsen, Malte M Tetens, Cecilie V Vollmond, Jan Gerstoft, Gitte Kronborg, Isik S Johansen, Carsten S Larsen, Lothar Wiese, Michael Dalager-Pedersen, Suzanne Lunding, Lars N Nielsen, Nina Weis, Niels Obel, Lars H Omland, Anne-Mette Lebech
doi : 10.1093/cid/ciad053
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1896–1902
Reproductive health in women with human immunodeficiency virus (HIV) (WWH) has improved in recent decades. We aimed to investigate incidences of childbirth, pregnancy, spontaneous abortion, and induced abortion among WWH in a nationwide, population-based, matched cohort study.
Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial
Belén P Solans, Marjorie Z Imperial, Morounfolu Olugbosi, Rada M Savic
doi : 10.1093/cid/ciad051
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1903–1910
Safer, better, and shorter treatments for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are an urgent global health need. The phase 3 clinical trial Nix-TB (NCT02333799) tested a 6-month treatment of MDR and XDR-TB consisting of high-dose linezolid, bedaquiline, and pretomanid (BPaL).
Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial
Cody P Doolan, Babak Sahragard, Jenine Leal, Anuj Sharma, Joseph Kim, Eldon Spackman, Aidan Hollis, Dylan R Pillai
doi : 10.1093/cid/ciad046
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1911–1918
Management of suspected Clostridioides difficile infection (CDI) in the hospital setting typically results in patient isolation, laboratory testing, infection control, and presumptive treatment. We investigated whether implementation of rapid near-patient testing (NPT) reduced patient isolation time, hospital length of stay (LOS), antibiotic usage, and cost.
Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
Bridget E Barber, Azrin N Abd-Rahman, Rebecca Webster, Adam J Potter, Stacey Llewellyn, Louise Marquart, Nischal Sahai, Indika Leelasena, Geoffrey W Birrell, Michael D Edstein, G Dennis Shanks, David Wesche, Joerg J Moehrle, James S McCarthy
doi : 10.1093/cid/ciad075
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1919–1927
The long-acting 8-aminoquinoline tafenoquine may be a good candidate for mass drug administration if it exhibits sufficient blood-stage antimalarial activity at doses low enough to be tolerated by glucose 6-phosphate dehydrogenase (G6PD)–deficient individuals.
The Antimalarial Activity of Tafenoquine in Falciparum Malaria
Nicholas J White
doi : 10.1093/cid/ciad079
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1928–1929
Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study
Michael Gottlieb, Ralph C Wang, Huihui Yu, Erica S Spatz, Juan Carlos C Montoy, Robert M Rodriguez, Anna Marie Chang, Joann G Elmore, Paavali A Hannikainen, Mandy Hill, Ryan M Huebinger, Ahamed H Idris, Zhenqiu Lin, Katherine Koo, Samuel McDonald, Kelli N O’Laughlin, Ian D Plumb, Michelle Santangelo, Sharon Saydah, Michael Willis, Lauren E Wisk, Arjun Venkatesh, Kari A Stephens, Robert A Weinstein, for the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
doi : 10.1093/cid/ciad045
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1930–1941
Most research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants focuses on initial symptomatology with limited longer-term data. We characterized prevalences of prolonged symptoms 3 months post–SARS-CoV-2 infection across 3 variant time-periods (pre-Delta, Delta, and Omicron).
The Influence of Rapid Influenza Diagnostic Testing on Clinician Decision-Making for Patients With Acute Respiratory Infection in Urgent Care
Brian D Stamm, John Tamerius, Sush Reddy, Shari Barlow, Caroline Hamer, Ashley Kempken, Maureen Goss, Cecilia He, Cristalyne Bell, Mitchell Arnold, Mary Checovich, Emily Temte, Derek Norton, Guanhua Chen, Jeffrey Baltus, Emily S Gurley, Jonathan L Temte
doi : 10.1093/cid/ciad038
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1942–1948
The potential benefits of using rapid influenza diagnostic tests (RIDTs) in urgent care facilities for clinical care and prescribing practices are understudied. We compared antiviral and antibiotic prescribing, imaging, and laboratory ordering in clinical encounters with and without RIDT results.
Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial
Giovanna Melica, Pablo Bartolucci, Etienne Audureau, Philippe Le Corvoisier, Anoosha Habibi, Justine Gellen, Dalia Selmane, Marc Michel, Christine Lacabaratz, Yves Levy
doi : 10.1093/cid/ciad037
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1949–1958
Patients with sickle cell disease (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD.
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment
Leonard A Sowah, Laura Smeaton, Irena Brates, Debika Bhattacharya, Benjamin Linas, Bruce Kreter, Sandra Wagner-Cardoso, Sunil Solomon, Mark Sulkowski, Gregory K Robbins
doi : 10.1093/cid/ciad034
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1959–1968
With the advent of efficacious oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV), identification of characteristics associated with adherence is critical to treatment success. We examined correlates of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial.
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study
Emma F Avery, Julia N Kleynhans, Bruno Ledergerber, Isabella C Schoepf, Christian W Thorball, Neeltje A Kootstra, Peter Reiss, Lene Ryom, Dominique L Braun, Maria C Thurnheer, Catia Marzolini, Marco Seneghini, Enos Bernasconi, Matthias Cavassini, Hélène Buvelot, Roger D Kouyos, Jacques Fellay, Huldrych F Günthard, Philip E Tarr, for the Swiss HIV Cohort Study
doi : 10.1093/cid/ciad033
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1969–1979
People with human immunodeficiency virus (HIV; PWH) have increased cardiovascular risk. Higher leukocyte count has been associated with coronary artery disease (CAD) events in the general population. It is unknown whether the leukocyte-CAD association also applies to PWH.
Prevalence and Clinical Outcomes of Respiratory Syncytial Virus vs Influenza in Adults Hospitalized With Acute Respiratory Illness From a Prospective Multicenter Study
Katherine M Begley, Arnold S Monto, Lois E Lamerato, Anurag N Malani, Adam S Lauring, H Keipp Talbot, Manjusha Gaglani, Tresa McNeal, Fernanda P Silveira, Richard K Zimmerman, Donald B Middleton, Shekhar Ghamande, Kempapura Murthy, Lindsay Kim, Jill M Ferdinands, Manish M Patel, Emily T Martin
doi : 10.1093/cid/ciad031
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1980–1988
Current understanding of severe respiratory syncytial virus (RSV) infections in adults is limited by clinical underrecognition. We compared the prevalence, clinical characteristics, and outcomes of RSV infections vs influenza in adults hospitalized with acute respiratory illnesses (ARIs) in a prospective national surveillance network.
Assessing the Diagnostic Performance of New Commercial Interferon-γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-Analysis
Edgar Ortiz-Brizuela, Lika Apriani, Tania Mukherjee, Sophie Lachapelle-Chisholm, Michele Miedy, Zhiyi Lan, Alexei Korobitsyn, Nazir Ismail, Dick Menzies Author Notes
doi : 10.1093/cid/ciad030
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 1989–1999
We compared 6 new interferon-γ release assays (IGRAs; hereafter index tests: QFT-Plus, QFT-Plus CLIA, QIAreach, Wantai TB-IGRA, Standard E TB-Feron, and T-SPOT.TB/T-Cell Select) with World Health Organization (WHO)–endorsed tests for tuberculosis infection (hereafter reference tests).
Disease Transmission by Patients With Subclinical Tuberculosis
Hai Viet Nguyen, Edine Tiemersma, Nhung Viet Nguyen, Hoa Binh Nguyen, Frank Cobelens
doi : 10.1093/cid/ciad027
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2000–2006,
Subclinical tuberculosis has been increasingly recognized as a separate state in the spectrum of the disease. However, evidence on the transmissibility of subclinical tuberculosis is still inconclusive.
The Time for Action Is Now: The Impact of Timing of Infectious Disease Consultation for Staphylococcus aureus Bacteremia
J Chase Cole, Christopher A Jankowski, Jorge L Verdecia, Carmen L Isache, Malleswari S Ravi, Yvette S McCarter, Anthony M Casapao
doi : 10.1093/cid/ciad110
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2007–2009
This retrospective cohort study was performed to compare clinical outcomes between patients with Staphylococcus aureus bacteremia who received an early versus late infectious disease consultation. Early consultation resulted in significantly greater adherence to quality care indicators and shorter hospital stays.
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)
Emma M Kileel, Carlos D Malvestutto, Janet Lo, Kathleen V Fitch, Carl J Fichtenbaum, Judith A Aberg, Markella V Zanni, Esteban Martinez, Nwora Lance Okeke, Princy Kumar, Esau Joao, Sara H Bares, Daniel Berrner, Marek Smieja, Jhoanna C Roa, Sara McCallum, Pamela S Douglas, Heather J Ribaudo, Steven K Grinspoon
doi : 10.1093/cid/ciad107
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2010–2013
Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m2/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years.
Effect of Coronavirus Disease 2019 Lockdowns on Identification of Advanced Human Immunodeficiency Virus Disease in Outpatient Clinics in Uganda
Elizabeth Nalintya, Preethiya Sekar, Paul Kavuma, Joanita Kigozi, Martin Ssuna, Paul Kirumira, Rose Naluyima, Teopista Namuli, Fred Turya Musa, Caleb P Skipper, Kathy Huppler Hullsiek, Jayne Ellis, David R Boulware, David B Meya, Radha Rajasingham
doi : 10.1093/cid/ciad087
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2014–2017
Using data from 67 Ugandan human immunodeficiency virus (HIV) clinics (July 2019–January 2022), we report a 40% (1005/1662) reduction in the number of people with HIV presenting to care after August 2021 compared to prepandemic levels, with a greater proportion presenting with advanced HIV disease (20% vs 16% in the pre–coronavirus disease 2019 period).
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M Bloch, Daniele Focosi, Shmuel Shoham, Jonathon Senefeld, Aaron A R Tobian, Lindsey R Baden, Pierre Tiberghien, David J Sullivan, Claudia Cohn, Veronica Dioverti, Jeffrey P Henderson, Cynthia So-Osman, Justin E Juskewitch, Raymund R Razonable, Massimo Franchini, Ruchika Goel, Brenda J Grossman, Arturo Casadevall, Michael J Joyner, Robin K Avery, Liise-anne Pirofski, Kelly A Gebo
doi : 10.1093/cid/ciad066
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2018–2024
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19.
A 65-Year-Old Woman With A Papulo-Spicular Rash Predominantly Affecting Her Nose
Arjun Chatterjee, Matthew J Franklin, Kyle D Brizendine
doi : 10.1093/cid/ciac681
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2025–2026
Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis
Jose A Perez-Molina, Clara Crespillo-Andújar, Javier Zamora, Borja M Fernández-Félix, Andrea Gaetano-Gil, Juan C López-Bernaldo de Quirós, Sergio Serrano-Villar, Santiago Moreno, Noelia Ã�lvarez-DÃaz, Juan Berenguer
doi : 10.1093/cid/ciad177
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2027–2037
We assessed whether low CD4 count and high viral load (VL) affect the response to currently preferred ART. We performed a systematic review of randomized, controlled clinical trials that analyzed preferred first-line ART and a subgroup analysis by CD4 count (≤ or >200 CD4/μL) or VL (≤ or >100 000 copies/mL).
Surveillance of Clostridioides difficile Antimicrobial Resistance in the United States
Anne J Gonzales-Luna, Chetna Dureja, Taryn A Eubank, Kevin W Garey, Julian G Hurdle
doi : 10.1093/cid/ciad135
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2038–2039
Reply to Gonzales-Luna et al
Amy S Gargis, Maria Karlsson, J Kamile Rasheed, Alyssa G Kent, Susannah L McKay, Ashley L Paulick, Karen F Anderson, Michelle Adamczyk, Davina Campbell, Lauren C Korhonen, Gillian McAllister, Nicholas Vlachos, Alison L Halpin, Joseph D Lutgring, Alice Y Guh, L Clifford McDonald, Christopher A Elkins
doi : 10.1093/cid/ciad133
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2039–2041
Revision of the Diagnostic Criteria for Infective Endocarditis Is Needed—Please Do It Thoroughly
Magnus Rasmussen, Andreas Berge
doi : 10.1093/cid/ciad120
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2041–2042
Reply to Author
Anders Dahl, Vance G Fowler, José M Miro, Niels E Bruun
doi : 10.1093/cid/ciad121
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2042–2043
Adjunctive Therapy With Clindamycin in Streptococcal Infection
Rosanne Sprute, Bernd Salzberger, Julia Götz, Norma Jung, Laura Stocker, Gerd Fätkenheuer
doi : 10.1093/cid/ciad104
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2043–2044
Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias
François Montastruc, Claire de Canecaude
doi : 10.1093/cid/ciad089
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2044–2045
Reply to Montastruc et al
Morgan Birabaharan, Thomas C S Martin, Sanjay R Mehta
doi : 10.1093/cid/ciad091
Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Page 2045
